Richard Schumacher Email

President, CEO and Director . Pressure BioSciences

Current Roles

Employees:
26
Revenue:
$3.5M
About
Following the sale of substantially all the assets and selected liabilities of its BBI Diagnostics and BBI Biotech Divisions to SeraCare Life Sciences, Inc. on September 14, 2004, Boston Biomedica, Inc. changed its name to Pressure BioSciences, Inc (PBI). PBI is a publicly traded, early-stage company focused on the development of a novel technology called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to control bio-molecular interactions. PBI currently holds 13 US and 4 foreign patents covering multiple applications of PCT in the life sciences field, including in such areas as genomic and proteomic sample preparation, pathogen inactivation, control of enzymes, immunodiagnostics, and protein purification. PBI owns a 30% passive investment in Source Scientific, LLC, an instrumentation company that develops and manufactures PBI\'s PCT equipment, as well as a passive investment of approximately 1 million shares in VI Technologies, an antiviral drug discovery and development company.
Pressure BioSciences Address
200 Boston Avenue
Medford, MA
United States

Past Companies

Pressure BioSciences, Inc.CEO, President, Board of Directors Member
Boston Biomedica, Inc.Founder, President, CEO, Board of Directors Member
Clinical Science LaboratoryDirector of Infectious Disease Services

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.